Travere Therapeutics (TVTX) Income towards Parent Company (2011 - 2026)
Travere Therapeutics posted quarterly Income towards Parent Company of -$500000.0 for Q1 2026, down 102.02% on a QoQ basis from $24.7 million in Q4 2025.
Travere Therapeutics (TVTX) has 16 years of Income towards Parent Company data on file, last reported at -$500000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company changed N/A year-over-year to -$500000.0; the trailing twelve-month figure through Mar 2026 stood at $24.2 million (up 3082.14% YoY), and the FY2025 full-year result was $24.7 million, up 2801.09% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$500000.0, down from $24.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $240.0 million in Q3 2023 and bottomed at -$1.6 million in Q4 2023.
- The 5-year median for Income towards Parent Company is $8.0 million (2022), against an average of $24.4 million.
- The widest annual swing landed in 2023, when Income towards Parent Company slumped 107.96%; it then soared 617775.0% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at $19.8 million in 2022, then tumbled by 107.96% to -$1.6 million in 2023, then soared by 100.25% to $4000.0 in 2024, then jumped by 617775.0% to $24.7 million in 2025, then slumped by 102.02% to -$500000.0 in 2026.
- The last three Income towards Parent Company figures came in at -$500000.0 (Q1 2026), $24.7 million (Q4 2025), and $4000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -500,000.00 |
| Dec 31, 2025 | 24.72 Mn |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -59,000.00 |
| Jun 30, 2024 | -757,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | 239.98 Mn |
| Jun 30, 2023 | 16.30 Mn |
| Mar 31, 2023 | 10.23 Mn |
| Dec 31, 2022 | 19.81 Mn |
| Sep 30, 2022 | 14.41 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |
| Mar 31, 2021 | -53.85 Mn |
| Dec 31, 2020 | -121.62 Mn |
| Sep 30, 2020 | -22.55 Mn |
| Jun 30, 2020 | -26.07 Mn |
| Mar 31, 2020 | 808,000.00 |
| Dec 31, 2019 | -30.26 Mn |
| Sep 30, 2019 | -36.49 Mn |
| Jun 30, 2019 | -38.70 Mn |
| Mar 31, 2019 | -40.98 Mn |
| Dec 31, 2018 | -7.46 Mn |
| Sep 30, 2018 | -54.52 Mn |
| Jun 30, 2018 | -22.33 Mn |
| Mar 31, 2018 | -18.38 Mn |
| Dec 31, 2017 | -17.62 Mn |
| Sep 30, 2017 | -17.79 Mn |
| Jun 30, 2017 | -13.23 Mn |
| Mar 31, 2017 | -11.09 Mn |
| Dec 31, 2016 | -8.60 Mn |
| Sep 30, 2016 | -37.11 Mn |
| Jun 30, 2016 | -13.40 Mn |
| Mar 31, 2016 | 11.22 Mn |
| Dec 31, 2015 | -2.47 Mn |
| Sep 30, 2015 | 105.58 Mn |
| Jun 30, 2015 | -25.53 Mn |
| Mar 31, 2015 | 39.66 Mn |
| Dec 31, 2014 | -29.03 Mn |
| Sep 30, 2014 | -17.98 Mn |
| Jun 30, 2014 | 11.81 Mn |
| Mar 31, 2014 | -75.74 Mn |
| Dec 31, 2013 | -12.75 Mn |
| Sep 30, 2013 | -12.01 Mn |
| Jun 30, 2013 | -4.92 Mn |
| Mar 31, 2013 | -4.87 Mn |
| Aug 31, 2012 | -3,500.00 |
| May 31, 2012 | -3,509.00 |
| Aug 31, 2011 | -3,525.00 |